Quick Asked: Volastra Therapeutics Contact Us?
Last update: 14 Apr, 2024 
325 Views
Listing Results Volastra Therapeutics Contact Us? Question Answers
Volastra Therapeutics Company Profile Office Locations
Volastra Therapeutics $24 m in total funding,. See insights on Volastra Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
VOLASTRA THERAPEUTICS, INC. :: New York (US) :: ...
Free and open company data on New York (US) company VOLASTRA THERAPEUTICS, INC. (company number 5596216), 150 WEST 28TH STREET, NEW YORK, NEW YORK, 10001
Aktis Oncology
Aktis Oncology is committed to transforming cancer care with novel platform technologies that will enable us to design and develop powerful precision radiopharmaceuticals. These are targeted therapies that safely harness the superior anticancer potency of alpha-emitting particles.
DNA Damage Response DDR Company Artios Pharma
Gillian also worked at Alizyme Therapeutics, Ark Therapeutics and Imutran Ltd, a Novartis Pharma AG company. At Ark Therapeutics Gillian was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (Phases 2 and 3).
Volastra Therapeutics Crunchbase Company Profile & ...
Headquarters Regions Greater New York Area, East Coast, Northeastern US. Founded Date 2019. Founders Lewis Cantley, Olivier Elemento, Samuel Bakhoum. Operating Status Active. Last Funding Type Seed. Legal Name Volastra Therapeutics, Inc. Company Type For Profit. Volastra Therapeutics is a biotechnology company developing novel therapies for the
Contact us Prime Therapeutics
855.457.0007 Contact Contact us Member services 855.457.0007 TTY users call 711 24 hours a day, 7 days a week 24-hour health care provider contact centers Plan specific phone numbers Corporate 800.858.0723 Prime Therapeutics, LLC 2900 Ames Crossing Road Eagan, MN 55121 Fraud tip hotline 800.731.3269 Contact Name First Last Which best describes you?
Lab Team Elemento Lab
(646) 962-7604 Volastra Therapeutics Contact Us. Weill Cornell Medicine Elemento Lab 413 E 69th St., Room 1404 New York, NY 10021 Phone: (646) 962-7604. Jump To Top. Our Location. Elemento Lab. Contact Us. 413 E 69th St., Room 1404 New York, NY ...
Volastra Therapeutics Commercial Real Estate News
Danny Meyer Invests In Expanding Taco Chain With Eyes On Taco Bell, Chipotle National Retail National Retail December 10, 2021 ; ...
Volastra Therapeutics and Dewpoint Therapeutics Partner to
Learn more at dewpointx.com, and follow us on Twitter and LinkedIn. Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.
Volastra Overview, News & Competitors ZoomInfo.com
(646) 344-1248 Frequently Asked Questions regarding Volastra Where are Volastra’s headquarters? Volastra’s headquarters are in 1361 Amsterdam Ave Suite 520, New York City, New York, 10027, United States What is Volastra’s phone number? Volastra’s phone number is (646) 344-1248 What is Volastra’s official website? Volastra’s official website is //volastratx.com
Targeting Hepatocyte Growth Factor Processing and
(314) 746-7290 Contact Us; Search; SBA Logo; Phone: (314) 746-7290 patients that fail to respond to targeted therapyCurrentlythere is no approved drug that would target HGFProteXase Therapeutics is developing the first small molecule inhibitors of HGF activationSynthetic HGF Activator InhibitorssHAIsWe have shown that sHAIs have potent anticancer
Researchers Identify Significant Differences in Tumor
Dr. Olivier Elemento is a paid scientific advisor and equity holder of Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. Dr. Olivier Elemento , Englander Institute for Precision Medicine , Government and Community Affairs , Research , News from WCM , Graduate School of Medical Sciences , Institute for Computational Biomedicine
Polaris Partners Crunchbase Investor Profile & Investments
855.787.3500 Investment Stage Early Stage Venture, Late Stage Venture, Seed. Number of Exits 164. Company Type For Profit. Contact Email partnership@ polarispartners.com. Phone Number 855.787.3500. Polaris Partners has over 20-year history partnering with repeat entrepreneurs and innovators who are improving the way people live and work. The multibillion
Dewpoint Overview, News & Competitors ZoomInfo.com
Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment NEW YORK and BOSTON, March 9, 2021 /PRNewswire/ -- Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates to prevent ...
News & Views • Volastra Volastra Therapeutics Home
(646) 344-1248 Volastra Therapeutics Expands Leadership Team to Tackle Cancer. Contact Us. Volastra 1361 Amsterdam Ave Suite 520 New York, NY 10027 Phone: (646) 344-1248 [email protected]. Media Contact Lisa Qu Ten Bridge Communications 678-662-9166 [email protected]. Volastra.
Volastra Therapeutics Stock / Share Price, Funding Rounds
Volastra Therapeutics investors. Polaris Partners, ARCH Venture Partners, Quark Venture, Vida Ventures, DROIA Oncology Ventures, Global Health Sciences Fund, Droia Ventures, Catalio Capital Management. Volastra Therapeutics's latest funding round in April 2021 was reported to be $12 m. In total, Volastra Therapeutics has raised $24 m.
Tarveda Therapeutics Email Format tarvedatx.com Emails
Tarveda Therapeutics Email Format. Tarveda Therapeutics uses 1 email formats, with first_initial last (ex. [email protected] ) being used 100.0% of the time. Get Verified Emails for Tarveda Therapeutics Employees. Tarveda Therapeutics's Email Format. Percentage.
M.A. in Biotechnology Program: News, Events, and
Volastra Therapeutics, Inc. is a biotechnology company based in New York City, formed from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum. Volastra is dedicated to the discovery and development of ...
VOLASTRA THERAPEUTICS, INC. · 150 West 28th Street, New
VOLASTRA THERAPEUTICS, INC. (DOS ID 5596216) is a corporation registered with New York State Department of State (NYSDOS). The initial filling date is July 31, 2019. The address is 150 West 28th Street, New York, NEW YORK 10001.
Volastra Therapeutics Launches with $12 Million in Seed
Volastra Therapeutics Launches with $12 Million in Seed Financing to Develop Novel Metastatic Cancer Therapies Polaris Partners led financing round for New York City-based start-up Company to
Home Auron Therapeutics
Dr. Michael Su joined Volastra as Chief Scientific Officer in February 2020. Previously, he served as CSO of Decibel Therapeutics, a gene therapy company focused on hearing loss and imbalance between 2016 and 2020. Michael was a co-founder and Senior Vice President of Research and Development at Agios Pharmaceuticals between 2008 and 2016.